Income statement
EUR
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 82M | 77M | 69M | 28M | 20M |
| Gross Profit | 21M | 28M | 3M | 12M | 12M |
| Operating Income | -9M | -3M | -27M | -3M | 2M |
| EBITDA | -443K | 5M | -18M | 732K | 5M |
| Net Income | -12M | -2M | -27M | -4M | 1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$6.38
+0.00% today
1Y Change
+39.55%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
FamiCord AG (VTIAF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $6.38 and up 39.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of +48.6%, a dividend yield of 0.0%. What stands out right now is revenue +7.2%, EPS +48.6%, free cash flow -104.6% with operating margin -2.6% and ROIC -2.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Stock Foundry combines VTIAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTIAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTIAF Max Drawdown
-8.93%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTIAF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$20.1M
-29.4% YoY
FY Net Income
$1.4M
+139.5% YoY
Free Cash Flow
$3.3M
+614.1% YoY
Revenue Growth
+7.2%
EPS Growth
+48.6%
Gross Margin
53.1%
Net Margin
-7.2%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 82M | 77M | 69M | 28M | 20M |
| Gross Profit | 21M | 28M | 3M | 12M | 12M |
| Operating Income | -9M | -3M | -27M | -3M | 2M |
| EBITDA | -443K | 5M | -18M | 732K | 5M |
| Net Income | -12M | -2M | -27M | -4M | 1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 17M | 16M | 33M | 10M |
| Total Assets | 153M | 158M | 152M | 178M | 58M |
| Total Liabilities | 140M | 136M | 136M | 136M | 29M |
| Shareholder Equity | 14M | 24M | 16M | 43M | 30M |
| Total Debt | 18M | 22M | 28M | 32M | 5M |
| Net Debt | 1M | 4M | 12M | -858K | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+45.9% YoY
Capital Expenditures
645K
+71.5% YoY
Free Cash Flow
3M
+614.1% YoY
Key ratios
Gross Margin
53.1%
Operating Margin
-2.6%
Net Margin
-7.2%
ROE
-52.7%
Debt / Equity
3.30x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.